ReviewCold Spring Harbor perspectives in medicine2020
Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.
Review in Cold Spring Harbor perspectives in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Exploring the perspectives of people who use drugs living with hepatitis C on interactions with case managers: A qualitative study in Taiwan.Belitung nursing journal · 2026Article
- Ethnic Disparities in Extrahepatic Manifestations Among People With HCV Infection: A Population-Based Study in British Columbia.Open forum infectious diseases · 2025Article
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations.JAMA network open · 2025Article
- Phytomolecules from Herbs: Possible Effective Way for the Treatment of Liver Cancer.Current topics in medicinal chemistry · 2025Review
- Review
- Anti-viral and Apoptotic Induction of m-TOR Inhibitor Drugs against Hepatitis C Virus Activity and Hepatocellular Carcinoma Cell Line: In vitro and in silico.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
- Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.Journal of clinical medicine research · 2023Article
- The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.Journal of clinical medicine · 2022Review
- Article
- Risk of hepatocellular carcinoma after hepatitis C virus cure.World journal of gastroenterology · 2022Review
- Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection.Hepatology (Baltimore, Md.) · 2021Article
- Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched.World journal of gastroenterology · 2021Review
- Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.PloS one · 2021Article
- Adaptive Immune Response against Hepatitis C Virus.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis C virus (HCV) infects 71.1 million persons and causes 400,000 deaths annually worldwide. HCV mostly infects the liver, causing acute and chronic necroinflammatory damage, which may progress toward cirrhosis and hepatocellular carcinoma. In addition, HCV has been associated with several extrahepatic manifestations. The advent of safe and effective direct-acting antivirals (DAAs) has made the dream of eliminating this public health scourge feasible in the medium term. Prospective studies using DAA-based regimens have shown the benefit of HCV clearance in terms of both liver- and non-liver-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.